🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — March 26, 2026

HHS dominates with $793M (45%) in health R&D contracts through 2029, signaling sustained federal priority on tobacco/health studies, biotech, and COVID immunogenicity amid $1.76B total modifications. Bullish signals for for-profit contractors Westat, AATD, and PPD highlight revenue visibility from high outlays ($122M-$213M disbursed) and options upside ($423M-$960M potential). Neutral nonprofits (Acacia, Advanced Tech) limit equity plays but underscore stable funding in refugee legal and BARDA biotech.

5 total filings
· daily

Contract Deobligations Alert — March 26, 2026

Deobligations alert reveals $1.76B in federal contracts with 3 bullish signals dominating (60% of records, $770M obligations) in HHS health R&D and VA IT services, signaling sustained funding flows. Neutral nonprofit awards ($993M) limit direct equity upside but underscore stable program spending in refugee legal aid and biotech. Investors should prioritize corporates/SDVOSBs with unexercised options (~$607M potential) amid long-term visibility to 2029.

5 total filings
· daily

Contract Option Exercises — March 26, 2026

Five contract option exercises totaling $1.76B highlight bullish signals for for-profit health R&D and VA IT providers (Westat, AATD LLC, PPD), with $770M obligated and strong outlays signaling revenue visibility through 2029. Neutral signals dominate two large nonprofit awards (Acacia, Advanced Technology International) totaling $993M, limiting direct equity upside. Investors should prioritize for-profit entities with unexercised options (~$707M potential) amid HHS/BARDA concentration (45% of value) in long-term R&D.

5 total filings
· daily

All HHS Contracts — March 26, 2026

HHS awarded $793M in health R&D contracts dominated by Westat's $505M PATH Study renewal (64% of total), signaling sustained federal commitment to longitudinal public health research through 2028. BARDA's $287M in biotech/COVID R&D awards to PPD and ATI provide multi-year visibility to 2029, though nonprofit ATI limits equity upside. Bullish for corporate contractors with optionality exceeding $1.2B potential value, but long tenors introduce funding risks amid shifting priorities.

3 total filings
· daily

Mega Contracts Monitor ($100M+) — March 26, 2026

HHS dominates with $792M in health R&D awards (PATH Study, biotech, COVID vaccines), signaling bullish multi-year funding visibility to 2029 for corporate contractors like Westat and PPD amid 3 bullish signals out of 5 contracts totaling $1.76B. DOI's $832M legal services contract for unaccompanied children underscores stable social services funding but neutral equity impact as a nonprofit. VA's $138M IT award highlights SDVOSB opportunities in federal tech services through 2026.

5 total filings
· daily

High-Value Federal Grants ($5M+) — March 26, 2026

High-value federal grants totaling $1.76B highlight sustained HHS funding for health R&D (PATH Study, BARDA biotech/COVID assays) and VA IT services, with 3 bullish signals for corporate/SDVOSB recipients providing multi-year revenue visibility through 2029. Neutral signals dominate nonprofits in legal/refugee services and early-stage biotech, limiting direct equity upside. Investors should prioritize for-profit health R&D and VA IT plays amid high outlay rates (e.g., 94% in Acacia, 88% in AATD) and unexercised options exceeding $700M across contracts.

5 total filings
· daily

General Federal Contracts — March 26, 2026

HHS dominates with $792M (45%) in health R&D contracts signaling bullish long-term revenue for Westat and PPD through 2028-2029, while DOI's $832M legal services award to nonprofit Acacia underscores stable migrant support funding. VA's $138M IT delivery order highlights SDVOSB opportunities with $423M potential upside for AATD. Overall $1.76B in awards emphasizes health/services durability but limits direct equity plays via nonprofits.

5 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 26, 2026

Across 13 filings from the S&P 500 Technology stream (with some cross-sector inclusions), dominant themes include neutral proxy statements for upcoming AGMs, mixed financial results highlighting cost discipline amid revenue softness, and selective growth in reserves/operations. Period-over-period trends show revenue declines averaging -5% YoY in reporting companies (e.g., Arcadia -4% FY2025, Q4 -26%), offset by operating expense cuts (Arcadia -15% FY, Mueller +24.4% op income YoY), with outliers like Mueller's record +10.9% sales and +26.5% net income. Critical developments: Mueller's 2030 plan targeting $1.5B op income, Arcadia's terminated deal and $2.1M cash infusion for growth, AParadise SPAC progress toward ENHA NYSE listing, and Canadian Natural's +4.5% proved reserves to 15,910 MMBOE. No insider trading activity reported across filings, limiting conviction signals; capital allocation shines with Mueller's $244M buybacks and 25% dividend hike. Portfolio implications: Tech exposure limited to stable Apple passive stake; monitor governance votes and May catalysts for alpha in industrials/biosciences proxies. Overall, cautious optimism from improving losses (+31-46% YoY in Arcadia) and strategic plans amid cash pressures.

7 high priority 6 medium 13 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 26, 2026

Across 24 NASDAQ-100 related SEC filings from March 26, 2026, overarching themes include cost discipline driving narrower losses in biotech/agrotech (Arcadia Biosciences FY loss improved 31% YoY to $2.3M, MetaVia net loss down 53% to $13M), robust industrial performance (CMC Q2 FY26 EBITDA +114% YoY to $297.5M, Mueller 2025 net income +26.5% YoY to $765M), and financing for growth (Keurig $5.55B notes for JDE Peet’s acquisition, Arcadia $2.1M proceeds). Period-over-period trends show mixed revenues (4/10 with declines avg -15% YoY, e.g., Arcadia -4% FY), but operating expenses down avg 25% YoY across reporting firms, boosting margins in winners like CMC (+610 bps to 14%). Resource firms added reserves (Canadian Natural +4.5% to 15,910 MMBOE via acquisitions), while proxies signal governance evolution (Murphy USA declassification). Neutral 13G amendments from Vanguard indicate passive shifts without ownership changes. Critical implications: Industrials offer strength amid sector rotation, biotechs present turnaround plays with cash runways into late 2026, but leverage risks loom in deals like Keurig's.

11 high priority 13 medium 24 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (primarily banks, insurers, REITs, asset managers amid broader microcap/SPAC noise), sentiment skews mixed/neutral (32/50 filings), with 12 companies reporting YoY revenue growth averaging +13% (e.g., Lumexa +7.8%, Leef Brands +22.1%) offset by 11 declines averaging -28% (e.g., CaliberCos -60.7%, STRATA -9%). Net losses narrowed in 9 firms (avg improvement 35%) but widened in 8 (avg +18%), highlighting persistent profitability challenges despite asset growth in credit investors (MSD +40.7%, AB Private +16.9%). SPAC/de-SPAC and M&A activity dominates (18 filings), signaling Q2 2026 catalysts with $500M+ proceeds (e.g., Xanadu, Suncrete). Capital allocation leans conservative: dividends in REITs (BlackRock $0.96/share), buybacks/dividends in retail proxies (Williams Sonoma $862M buybacks + $327M divs), no major cuts. Forward-looking guidance stable (Lumexa reiterates 2026 rev $1.045-1.097B), but risks from delistings (FiscalNote), going concerns (Indigo SPAC), and leverage rises. Portfolio implications: Bullish on SPAC mergers and credit growth; bearish on revenue-dependent microcaps; watch NIM/ROE trends in banks/insurers for rate sensitivity.

37 high priority 13 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via trusts and adjacents), proxy statements dominate (e.g., ADM, Newell, Philip Morris, Oshkosh) signaling peak governance season with May 2026 AGMs, board recommendations FOR comp plans/auditors amid neutral sentiment. Period-over-period trends show mixed revenue growth (e.g., Insight Molecular +116% YoY, Interlink +1.8% YoY, Worthington Steel +12% Q3 YoY) offset by widespread margin compression (Interlink gross -270bps YoY, Rockwell Q4 flat at 21% but FY sales -32% YoY) and cash deteriorations (Eltek ops cash -75% YoY to $1.1M, Rockwell ops cash used $659k vs provided $4.2M prior). Capital allocation leans shareholder-friendly in outliers (Oshkosh dividend +11.8% to $0.57, cash returned +73% YoY) but debt-heavy for M&A (Keurig €3B+$2.55B notes for JDE Peet’s). Forward-looking catalysts cluster in FDA reviews (Insight Q3 2026), acquisitions (Keurig by Feb 2027), and AGMs, with bullish alpha in diagnostics/health adjacents but bearish pressures from macro risks (Kornit inflation/overcapacity). Portfolio-level: 12/50 filings show revenue growth >10% YoY, but 8/20 with margin data average -150bps compression; staples-specific neutral on governance, mixed on financing.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like materials and construction amid sparse pure industrials), proxy season dominates with 15+ DEF/DEFA14A filings scheduling May 2026 annual meetings, signaling routine governance amid neutral-to-positive sentiment on board refreshes and comp approvals. FY2025 financials reveal mixed trends: revenue growth in select names like Paychex (+19.8% YoY Q3) and Iridex (+8% FY), but widespread loss widening in biotechs (e.g., Acumen +19%, Upstream +128%) and margin pressures (e.g., Evogene gross loss from inventory impairment); banks show NIM expansion (Farmers & Merchants +34 bps to 3.02%) offset by deposit declines (-5%). Capital returns shine with Newmont's $1.1B dividends/$3B buybacks and Banc of California's 8% share repurchase, while forward catalysts cluster in Q2 2026 (Rhythm EMA approval, multiple AGMs). Portfolio-level patterns include cost discipline (R&D/G&A cuts in 7/12 10-Ks averaging -25% YoY) amid cash burn, biotech regulatory tailwinds, and M&A like Corebridge-Equitable all-stock deal for $1.5T AUM scale. Implications: tactical buys in outperforming industrials like GE (passive Vanguard stake) and Newmont, caution on biotech cash drains; alpha from May proxy-driven volatility and Q2 catalysts.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 26, 2026

Across 12 SEC filings in the USA S&P 500 Energy intelligence stream (including midstream and LNG players like Targa Resources, Williams Companies, and Golar LNG), overarching themes include robust revenue growth in select reporters (e.g., Golar LNG +51% YoY, Galapagos NV +304% YoY) offset by rising costs, impairments, and margin pressures, with Williams Sonoma net earnings -3.3% YoY despite +1.2% revenue. Governance activity dominates with multiple proxy statements and board changes, notably Williams Companies reducing board size post-Alan Armstrong's resignation for U.S. Senate role, signaling leadership transitions in energy midstream. Capital allocation shows shareholder returns via buybacks ($862M at Williams Sonoma) and dividends ($327M), alongside capital raises like Peapack-Gladstone's $50M preferred stock. Forward-looking catalysts cluster around April-May 2026 AGMs and events like Enhanced Games launch, amid mixed sentiment (5/12 mixed or negative). Portfolio-level trends reveal 3/5 financial reporters with YoY revenue acceleration (avg +119%) but operating challenges (e.g., Golar expenses +31%, Galapagos R&D +37%), implying selective growth opportunities in energy services/LNG versus broader cost headwinds. Market implications favor monitoring midstream governance stability and LNG revenue momentum for near-term positioning.

10 high priority 2 medium 12 total filings
· daily

US Material Events SEC 8-K Filings — March 26, 2026

Across 50 US SEC 8-K filings dated March 26, 2026, the dominant themes are pervasive executive turnover (20+ resignations/appointments across C-suite and boards), aggressive financing activity ($7M PIPE at Health In Tech, $475.9M at Wolfspeed, $250M credit at Stone Point), major M&A/divestitures (OLAPLEX buyout at 55% premium, Equitable-Corebridge $22B merger, SSR Mining $1.5B sale), and debt restructurings/extensions signaling liquidity strains in smaller caps. Limited period-over-period data shows Interlink Electronics with Q4 2025 revenue -4.5% YoY to $2.853M, gross margins -790 bps to 31.7%, but FY revenue +1.8% to $11.89M; no broad portfolio trends due to event-driven nature, but positive capital raises contrast one bankruptcy (Broad Street Realty). Critical developments include accretive mergers (Equitable-Corebridge >10% EPS accretion by 2028E), premium acquisitions, and experienced exec hires (Bloom Energy CFO, Vitesse CEO), implying sector transitions in energy/tech/finance; bearish signals from resignations and debt waivers highlight turnover risks. Market implications: Opportunities in M&A catalysts and post-financing pops, but watch liquidity/distress in microcaps amid high dilution risks.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 26, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily FY2025 10-Ks, 8-Ks, and proxy statements), overarching themes include a wave of proxy filings signaling May 2026 annual meetings for governance votes, mixed FY2025 financials with average revenue declines of ~12% YoY in 15/20 reporting companies (e.g., Shoe Carnival -5.6%, VirTra -15%, Identiv -19%) offset by cost cuts and margin improvements in 8/15 (e.g., CV Sciences gross margin +340 bps to 49%), and selective growth outliers like Galapagos NV +304% revenues to €1.11B. Capital allocation leans positive with dividend hikes (Shoe Carnival +11% to $0.60, Oshkosh +11.8% to $0.57) and buybacks (Banc of California 8% shares repurchased), but dilution risks from warrant exercises (Wheeler REIT 12% new shares) and shelf registrations (Kyverna $300M). Leadership transitions (Vitesse CEO change, CNH directors not re-electing) and biotech catalysts (Kyverna BLA 1H2026) provide upside, while retail/consumer and SPACs show weakness amid macro pressures. Portfolio-level, financials/banks exhibit NIM expansion (Hoyne +86 bps to 3.24%, Farmers & Merchants +34 bps to 3.02%), contrasting tech/manufacturing declines. Implications: Near-term proxy-driven volatility low materiality; focus on turnaround plays and dividend growers for defensive positioning.

27 high priority 23 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 26, 2026

Across 50 SEC filings for March 26, 2026, FY2025 results dominate with mixed outcomes: 14/22 10-Ks showed revenue growth averaging +15% YoY (e.g., Lumexa +7.8%, TXO +41.8%, Leef Brands +22.1%), but 10 reported widening net losses or impairments amid higher expenses/impairments (avg net loss expansion +12% YoY), signaling margin pressures in retail/REITs (Noodles -17.5% net loss YoY). SPAC/de-SPAC and M&A activity surges (12 filings, e.g., Suncrete non-redemptions +$105M PIPE, Xanadu $500M proceeds), indicating capital inflow for tech/quantum/industrials despite redemptions risks. Capital allocation leans shareholder-friendly (Williams Sonoma $862M buybacks + $327M dividends; News Corp $1B repurchase), but delistings (FiscalNote NYSE suspension) and delays (Genie Energy restatements, American Strategic earnings reschedule to Apr 14) flag governance risks. Healthcare outliers: Lumexa bullish (EBITDA +14.6% YoY, 2026 guidance $1.045-1.097B rev) vs Strata Skin rev -9% YoY. Energy mixed (TXO rev +42% but impairments; Canadian Nat reserves +4.5%). Portfolio implication: Favor growth diagnostics/energy over distressed retail/REITs; monitor SPAC closings for April catalysts.

35 high priority 15 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (broadly including retail, auto, gaming/entertainment proxies), overarching themes reveal mixed financial performance with revenue growth in 6/14 key operational reporters averaging +10% YoY (e.g., Ulta +9.7%, Laird +15%, SKYX +7%) offset by widespread margin compression averaging -120 bps (Laird -300 bps, Ulta -150 bps, Oxford ongoing pressures). Capital allocation leans shareholder-friendly with dividend hikes (Oxford to $0.70/share, First Bancorp declaration) and buybacks (Banc of California 8% shares repurchased), while M&A/integration (Laird/Navitas $38.5M) and debt optimization (Wolfspeed -43% notes redeemed, -13% debt) signal resilience. Proxies dominate (18/50 filings) clustering annual meetings in May 2026, highlighting governance catalysts amid neutral-to-positive sentiment. Portfolio-level trends show 4/10 consumer-facing firms guiding modest 2026 growth despite tariffs/commodity headwinds, with infra/funds (KKR +111% net ops) outperforming pure plays. Critical developments include Ulta's store expansion to 1,591 (+10%) and SKYX's gross margin to 30% (+100 bps), implying selective alpha in resilient retail/gaming vs. broader deterioration in legacy assets.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 26, 2026

Across 50 filings from the S&P 500 Healthcare stream and adjacent sectors, proxy statements dominate (e.g., Edwards Lifesciences, Centene, Alto Neuroscience) with neutral sentiment, setting up May 2026 annual meetings as key catalysts for director elections, auditor ratifications, and equity plan approvals. Financial results are mixed: small biotechs like Dare Bioscience (+10,429% YoY revenue from licenses) and STRATA Skin Sciences (-9% revenue but +49% operating loss improvement) show cost discipline narrowing losses despite revenue softness, while providers like Centene report challenging 2025 EPS ($2.08) but guide >$3.00 for 2026 (+40% YoY growth). Non-healthcare outliers like Corebridge Financial's $22B all-stock merger with Equitable (51/49 ownership split, $500M synergies by 2028, close YE2026) and Newmont's record 2025 FCF/$3B buybacks highlight capital returns, but healthcare trends emphasize R&D cuts (Dare -61% YoY) and positive pipeline catalysts (Artelo/Wave). Aggregate period trends: 7/12 reporting companies saw revenue declines averaging -10% YoY (e.g., CV Sciences -12%, STRATA -9%), but operating losses improved in 6/8 cases (avg +35% narrowing), signaling efficiency amid growth headwinds. Forward-looking optimism in biotech (e.g., Newsmax 13% rev growth FY26, though non-HC) contrasts with cash burn risks (Arcadia cash to $259K). Portfolio implication: Favor cost-cutters like Dare/CV Sciences for turnaround; monitor May proxies for governance shifts.

33 high priority 17 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 26, 2026

Across 50 DEF 14A proxy statements filed around March 26, 2026, a dominant theme is robust 2025 financial performance with 18/50 companies highlighting YoY revenue growth (avg +15% where quantified, e.g., Advanced Energy +21%, Liberty Media F1 +14%), record FCF in energy peers (CNX $646M, Peabody solid cash flow), and aggressive capital returns via buybacks ($3B Newmont, $528M CNX, 8% shares Banc CA) and dividend hikes (Oshkosh +11.8%, Hanover +5.6%). Exec comp is performance-aligned (79-95% at-risk/at equity in Tradeweb, Tractor Supply 89% variable), with high say-on-pay support (94.2% Eastern Bankshares, but KLX only 44.9%). Mixed signals in healthcare (Centene adj EPS $2.08 below outlook but 2026 >$3.00 +40% growth) and industrials (Oshkosh revenue -2.9% YoY). Governance strong: avg 85% board independence, diversity up (Tradeweb 55% indep, Invitation 40% diverse). No widespread insider selling noted; buybacks signal conviction. Portfolio trend: Bullish resource/energy (12/15 positive sentiment), neutral tech/healthcare; May 2026 meetings as catalysts for comp votes, declassifications.

50 high priority 50 total filings